Accounting firms that are best positioned to capture the growth from advisory services must do more than rethink the services ...
Beam is now in the strongest position of all companies advancing a genetic therapy for alpha-1 antitrypsin deficiency, according to analysts at William Blair. Beam Therapeutics’ investigational base ...
CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE)-- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced updated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results